http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113440533-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb351a5a4e03ee3773bd0df5dbae9ac3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
| filingDate | 2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29aba33db520c68505f985286740ad93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d20afe4a1c0eafa9b597b8ae8a77783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04cd03fda2a3648e23dc91b96e6c9606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38edf26f8cf1bdcb15b7b5b55b808c6d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f3c4b355b8db07bc72d580174bd7006 |
| publicationDate | 2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113440533-A |
| titleOfInvention | Application of stachyose in the preparation of medicaments for the treatment of castration-resistant prostate cancer |
| abstract | The invention discloses the application of stachyose in the preparation of a medicament for treating castration-resistant prostate cancer, and belongs to the technical field of biomedicine. The present invention proposes for the first time a new strategy of using stachyose in combination with androgen receptor antagonists to prepare a drug for treating CRPC, and conducts multi-angle and multi-level verification research. The pharmaceutical composition of stachyose combined with androgen receptor of the present invention can be used for the treatment of castration-resistant prostate cancer, and can significantly improve the effect of enzalutamide in inhibiting castration-resistant prostate cancer, and the natural compound can be applied to advanced cancer , has important clinical significance. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114225043-A |
| priorityDate | 2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.